Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
Sagimet Biosciences (Nasdaq: SGMT) has announced its participation in the UBS Global Healthcare Conference. The clinical-stage biopharmaceutical company, which focuses on developing therapeutics for metabolic and fibrotic pathways, will engage in a fireside chat on Wednesday, November 13, 2024, at 5 p.m. PST in Rancho Palos Verdes, California.
The event will be accessible via webcast through Sagimet's website in the Investors & Media section, with replay availability for 90 days after the live presentation.
Sagimet Biosciences (Nasdaq: SGMT) ha annunciato la sua partecipazione al UBS Global Healthcare Conference. L'azienda biofarmaceutica in fase clinica, che si concentra nello sviluppo di terapie per le vie metaboliche e fibrotiche, parteciperà a una chiacchierata informale mercoledì 13 novembre 2024, alle 17:00 PST a Rancho Palos Verdes, California.
L'evento sarà accessibile tramite webcast sul sito di Sagimet nella sezione Investitori e Media, con possibilità di riproduzione per 90 giorni dopo la presentazione dal vivo.
Sagimet Biosciences (Nasdaq: SGMT) ha anunciado su participación en la UBS Global Healthcare Conference. La empresa biofarmacéutica en etapa clínica, que se enfoca en el desarrollo de terapias para vías metabólicas y fibrosas, participará en una charla informal el miércoles 13 de noviembre de 2024 a las 5 p.m. PST en Rancho Palos Verdes, California.
El evento será accesible a través de una transmisión web en el sitio de Sagimet en la sección de Inversores y Medios, con disponibilidad de repetición durante 90 días después de la presentación en vivo.
사기멧 바이오사이언스 (Nasdaq: SGMT)는 UBS 글로벌 헬스케어 컨퍼런스에서의 참여를 발표했습니다. 대사 및 섬유 경로를 위한 치료제를 개발하는 데 주력하는 임상 단계 생명공학 회사인 사기멧은 2024년 11월 13일 수요일 오후 5시 PST에 캘리포니아주 랜초 팔로스 베르데스에서 대화에 참여할 예정입니다.
이번 행사는 사기멧 웹사이트의 투자자 및 미디어 섹션을 통해 웹캐스트로 시청 가능하며, 생중계 이후 90일 동안 다시 볼 수 있습니다.
Sagimet Biosciences (Nasdaq: SGMT) a annoncé sa participation à la UBS Global Healthcare Conference. L'entreprise biopharmaceutique en phase clinique, qui se concentre sur le développement de thérapies pour les voies métaboliques et fibroses, participera à une discussion informelle le mercredi 13 novembre 2024 à 17h PST à Rancho Palos Verdes, Californie.
L'événement sera accessible via un webcast sur le site web de Sagimet dans la section Investisseurs et Médias, avec une disponibilité de rediffusion pendant 90 jours après la présentation en direct.
Sagimet Biosciences (Nasdaq: SGMT) hat seine Teilnahme an der UBS Global Healthcare Conference bekannt gegeben. Das Unternehmen in der klinischen Phase, das sich auf die Entwicklung therapeutischer Ansätze für metabolische und fibrotische Wege konzentriert, wird am Mittwoch, den 13. November 2024, um 17:00 Uhr PST in Rancho Palos Verdes, Kalifornien, an einem informellen Gespräch teilnehmen.
Die Veranstaltung wird über einen Webcast auf der Webseite von Sagimet im Bereich Investoren und Medien zugänglich sein, mit einer Wiederholung, die 90 Tage nach der Live-Präsentation verfügbar ist.
- None.
- None.
SAN MATEO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, November 13, 2024 at 5 p.m. PST in Rancho Palos Verdes, California.
A webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of MASH. FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. For additional information about Sagimet, please visit www.sagimet.com.
Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Source: Sagimet Biosciences Inc.
FAQ
When is Sagimet Biosciences (SGMT) presenting at the UBS Global Healthcare Conference 2024?
How long will the replay of Sagimet's (SGMT) UBS Conference presentation be available?
Where can I watch Sagimet Biosciences' (SGMT) UBS Conference presentation?
What type of presentation will Sagimet (SGMT) give at the UBS Healthcare Conference?
